Poster Poster Program Radiopharmaceuticals, Theranostics, and Nuclear Medicine

Normal-Organ Effective Half-Lives for 177Lu-PSMA

Abstract
Purpose

To report effective half-lives of normal organs and investigate the relationship between kidney effective half-life and creatinine clearance in patients undergoing 177Lu-PSMA-617 therapy at our institution. As single-timepoint dosimetry relies on patient-kinetics matching well with population kinetics, this study addresses the current scarcity of reported effective half-life values.

Methods

Twenty patients undergoing 177Lu-PSMA-617 therapy with post-treatment dosimetry were analyzed, each imaged with SPECT/CT at 4-, 24-, 48-, and 72-hours post-administration. Reasons for dosimetry included: re-treatment (n= 1), solitary kidney (n=3), lung disease (n=4), renal disease (n=2). Regions analyzed were the kidneys (n=37), lungs (n=40), liver (n=20), spleen (n=20), parotid gland (n=38), and bone marrow (n=20). Organs were contoured in MIM Software (MIM Software, Cleveland, OH) using MIM Contour ProtégéAI, and a representative bone marrow region was contoured within lumbar vertebrae. Effective half-lives were estimated by fitting a monoexponential model to activity concentration data using the SciPy (v1.17.0) curve-fitting function in Python. Creatinine clearance was estimated from serum creatinine using the Cockcroft-Gault formula. For each region, descriptive statistics (mean, median, IQR, range) were calculated. Spearman’s rank correlation was used to examine the relationship between kidney effective half-life and creatinine clearance.

Results

Median effective half-lives (range) were: kidneys 35.5 h (8.5-152.0), lungs 15.1 h (7.4-160.8), liver 22.9 h (12.9-63.4), spleen 16.8 h (9.3-149.7), parotid gland 42.2 h (18.9-160.8), and bone marrow 32.0 h (5.9-160.8). No correlation was found between kidney half-life and creatinine clearance (p=0.278).

Conclusion

Effective half-lives for kidney and liver were comparable to those reported in literature. However, the parotid gland effective half-life was higher than reported values, and published values could not be found for image-based red marrow, lungs, or spleen. Outliers were present in each organ, which warrants future investigation to identify characteristics of patients with normal clearance to qualify candidates for single-timepoint dosimetry.

People

Related

Similar sessions

Poster Poster Program
Jul 19 · 07:00
Adverse Events in Targeted Radionuclide Therapy

Radiopharmaceutical therapy (RPT) plays an important role in the management of oncology patients, particularly those with thyroid cancer, prostate cancer, and neuroendocrine tumor. The use of radionuclide therapy has expanded rap...

Harrison L. Agordzo
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Development of a Web-Based Theranostic Workflow Management Tool

To develop a Web-Based Theranostic Workflow Management Tool (TWMT) to efficiently manage Theranostic program in the department of radiation oncology (RadOnc).

Ling Zhuang, PhD
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Epidseg-Net:the Multi-Modal Fusion Framework Based on Drr Guidance In Radiotherapy Is Used for Precise Segmentation of Epid Lung Targets

The proposed multimodal segmentation framework, named EPIDSeg-Net, comprises an encoder, a multi-scale feature layer, and a decoder. The encoder utilizes a dual-branch architecture: a CNN branch for extracting local texture featu...

Huang Qian Qianjia, M.Eng
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested